This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Abe-Hashimoto, J. Articles by Ikeda, K. Search for Related Content PubMed PubMed Citation Articles by Abe-Hashimoto, J. Articles by Ikeda, K.

Antitumor Effect of 22-Oxa-calcitriol, a Noncalcemic Analogue of Calcitriol, in Athymic Mice Implanted with Human Breast Carcinoma and Its Synergism with Tamoxifen¹

Research Laboratories, Chugai Pharmaceutical Co., Ltd., Tokyo 171 [J. A-H., Y. N.], and Division of Endocrinology, Fourth Department of Internal Medicine, University of Tokyo School of Medicine, Tokyo 112 [T. K., T. M., E. O., K. I.], Japan

The antitumor effect of 22-oxa-calcitriol (OCT), a newly developed noncalcemic analogue of calcitriol, was examined in vivo in athymic mice implanted with human breast carcinoma with or without estrogen receptor (ER). In ER-positive MCF-7 tumor, the growth of which was dependent on exogenous estrogen, administration p.o. of OCT as well as the antiestrogen tamoxifen five times a week for 4 weeks suppressed tumor growth in a dose-related fashion. The antitumor effect of 1.0 µg/kg body weight (BW) OCT (mean ± SEM of tumor weight in 6 mice: 28 ± 4% of vehicle-treated group) was comparable to that of 2.0 mg/kg BW tamoxifen (25 ± 6% of control group). In addition, a synergistic antitumor effect of submaximal doses of OCT and tamoxifen was observed in MCF-7 tumor in vivo as well as in ER-positive breast carcinoma cell lines (MCF-7 and ZR-75-1) in vitro. Administration of OCT p.o. three times a week for 4 weeks also suppressed the growth of ER-negative MX-1 tumor in a dose-dependent manner without raising serum calcium concentrations. The antitumor effect of 1.0 µg/kg BW OCT (mean ± SEM of tumor weight in 10 mice: 44 ± 6% of vehicle-treated group) was greater than that of 500 µg/kg BW Adriamycin (71 ± 6% of control group). These results indicate that OCT suppresses the growth of ER-negative as well as ER-positive breast carcinoma in vivo without causing hypercalcemia and that the antitumor effect of OCT can be enhanced by tamoxifen in an ER-positive tumor. It is suggested that OCT may provide a new strategy, either alone or in combination with other anticancer drugs, for systemic adjuvant therapy of breast carcinoma regardless of ER status.

¹ Supported in part by Grants-in-Aid for Encouragement of Young Scientists (K. I.) and for Scientific Research (T. M.) from the Ministry of Education, Science and Culture of Japan and grants from the Japan Research Foundation for Clinical Pharmacology (K. I.) and from Uehara Memorial Foundation (K. I.).

² Present address: Cancer Institute, Tokyo 170, Japan.

³ To whom requests for reprints should be addressed, at Division of Endocrinology, Fourth Department of Internal Medicine, University of Tokyo School of Medicine, 3-28-6 Mejirodai, Bunkyo-ku Tokyo 112, Japan.

Received 12/30/92. Accepted 3/26/93.

This article has been cited by other articles:

				N. Urushino, S. Nakabayashi, M. A. Arai, A. Kittaka, T. C. Chen, K. Yamamoto, K. Hayashi, S. Kato, M. Ohta, M. Kamakura, et al. Kinetic Studies of 25-Hydroxy-19-nor-vitamin D3 and 1{alpha},25-Dihydroxy-19-nor-vitamin D3 Hydroxylation by CYP27B1 and CYP24A1 Drug Metab. Dispos., September 1, 2007; 35(9): 1482 - 1488. [Abstract] [Full Text] [PDF]

				G. E. Mullin and A. Dobs Vitamin D and Its Role in Cancer and Immunity: A Prescription for Sunlight Nutr Clin Pract, June 1, 2007; 22(3): 305 - 322. [Abstract] [Full Text] [PDF]

				S. Masuda and G. Jones Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther., April 1, 2006; 5(4): 797 - 808. [Abstract] [Full Text] [PDF]

				T. M. Beer, M. Javle, G. N. Lam, W. D. Henner, A. Wong, and D. L. Trump Pharmacokinetics and Tolerability of a Single Dose of DN-101, a New Formulation of Calcitriol, in Patients with Cancer Clin. Cancer Res., November 1, 2005; 11(21): 7794 - 7799. [Abstract] [Full Text] [PDF]

				K. Nakagawa, Y. Sasaki, S. Kato, N. Kubodera, and T. Okano 22-Oxa-1{alpha},25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer Carcinogenesis, June 1, 2005; 26(6): 1044 - 1054. [Abstract] [Full Text] [PDF]

				T. M. Beer and A. Myrthue Calcitriol in cancer treatment: From the lab to the clinic Mol. Cancer Ther., March 1, 2004; 3(3): 373 - 381. [Abstract] [Full Text]

				M. Danilenko, X. Wang, and G. P. Studzinski Carnosic Acid and Promotion of Monocytic Differentiation of HL60-G Cells Initiated by Other Agents J Natl Cancer Inst, August 15, 2001; 93(16): 1224 - 1233. [Abstract] [Full Text] [PDF]

				K.-I. Takeyama, Y. Masuhiro, H. Fuse, H. Endoh, A. Murayama, S. Kitanaka, M. Suzawa, J. Yanagisawa, and S. Kato Selective Interaction of Vitamin D Receptor with Transcriptional Coactivators by a Vitamin D Analog Mol. Cell. Biol., February 1, 1999; 19(2): 1049 - 1055. [Abstract] [Full Text] [PDF]

				G. Wu, R. S. Fan, W. Li, V. Srinivas, and M. G. Brattain Regulation of Transforming Growth Factor-beta Type II Receptor Expression in Human Breast Cancer MCF-7 Cells by Vitamin D3 and Its Analogues J. Biol. Chem., March 27, 1998; 273(13): 7749 - 7756. [Abstract] [Full Text] [PDF]